Next Article in Journal
Activation Studies of the β-Carbonic Anhydrase from the Pathogenic Protozoan Entamoeba histolytica with Amino Acids and Amines
Next Article in Special Issue
Nicotinamide and NAFLD: Is There Nothing New Under the Sun?
Previous Article in Journal
Metabolic Alterations in Male-Sterile Potato as Compared to Male-Fertile
Retraction published on 11 April 2019, see Metabolites 2019, 9(4), 70.
Open AccessReview

The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD)

Division of Gastroenterology, Department of Medical Specialties, University of Modena and Reggio Emilia, 41124 Modena, Italy
*
Author to whom correspondence should be addressed.
Metabolites 2019, 9(2), 25; https://doi.org/10.3390/metabo9020025
Received: 31 December 2018 / Revised: 26 January 2019 / Accepted: 30 January 2019 / Published: 1 February 2019
(This article belongs to the Special Issue Metabolism and Metabolomics of Liver in Health and Disease)
Nonalcoholic fatty liver disease (NAFLD) is a common cause of hepatic abnormalities worldwide. Nonalcoholic steatohepatitis (NASH) is part of the spectrum of NAFLD and leads to progressive liver disease, such as cirrhosis and hepatocellular carcinoma. In NASH patient, fibrosis represents the major predictor of liver-related mortality; therefore, it is important to have an early and accurate diagnosis of NASH. The current gold standard for the diagnosis of NASH is still liver biopsy. The development of biomarkers able to predict disease severity, prognosis, as well as response to therapy without the need for a biopsy is the focus of most up-to-date genomic, transcriptomic, proteomic, and metabolomic research. In the future, patients might be diagnosed and treated according to their molecular signatures. In this short review, we discuss how information from genomics, proteomics, and metabolomics contribute to the understanding of NAFLD pathogenesis. View Full-Text
Keywords: nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; Fibrosis; Liver biopsy; Genomics; Metabolomics; Proteomics; Transcriptomics nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; Fibrosis; Liver biopsy; Genomics; Metabolomics; Proteomics; Transcriptomics
Show Figures

Figure 1

MDPI and ACS Style

Carulli, L.; Zanca, G.; Schepis, F.; Villa, E. The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD). Metabolites 2019, 9, 25.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop